4.5 Article

Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma

Journal

DIGESTIVE AND LIVER DISEASE
Volume 41, Issue 12, Pages 902-906

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.dld.2009.04.013

Keywords

Cirrhosis; Endothelial progenitor cells; Hepatocellular carcinoma; Portal hypertension

Ask authors/readers for more resources

Background and aims: Circulating endothelial progenitor cells have a negative prognostic impact in patients with hepatocellular carcinoma, but may play a different role in portal hypertension according to preclinical data. Here, we address this issue for the first time in cirrhotic patients +/- hepatocellular carcinoma. Methods: Portal hypertension in cirrhotic and hepatocellular carcinoma patients was determined by hepatic venous pressure gradient. Blood cells staining positive for CD34/KDR/AC133 using flow cytometry were characterised as endothelial progenitor cells. Vascular endothelial growth factor levels were determined by ELISA. Results: Endothelial progenitor cells levels in peripheral blood were elevated in cirrhotic (n = 23) (mean: 0.12 +/- 0.06% S.D.) and in hepatocellular carcinoma patients (n = 24) (0.14 +/- 0.09% S.D.) relative to healthy controls (H-group, n = 15) (0.06 +/- 0.04% S.D.) (P = 0.056 and P = 0.02, respectively). There were higher vascular endothelial growth factor levels in hepatocellular carcinoma patients compared to cirrhotics (P = 0.047) and HC (P = 0.037). Notably, hepatic venous pressure gradient was positively correlated with vascular endothelial growth factor(r = 0.5, P = 0.046) but negatively with endothelial progenitor cells levels (r = -0.51, P = 0.02) in cirrhotics, but not hepatocellular carcinoma patients. Conclusion: Circulating endothelial progenitor cells are increased in patients with portal hypertension +/- hepatocellular carcinoma. The negative correlation of endothelial progenitor cells with hepatic venous pressure gradient suggests a protective role of endothelial progenitor cells in liver cirrhosis whilst vascular endothelial growth factor is associated with high hepatic venous pressure gradient. In contrast, increased endothelial progenitor cells in hepatocellular carcinoma rather reflect turnout specific endothelial progenitor cells mobilisation. (C) 2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Gastroenterology & Hepatology

MAFLD, HCC and the dilemma of (changing) terminology in liver diseases

Ruben Hernaez, Markus Peck-Radosavljevic

Article Immunology

Low Spontaneous Clearance Rates of Recently Acquired Hepatitis C Virus in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men (PROBE-C Study)

Malte B. Monin, Patrick Ingiliz, Thomas Lutz, Stefan Scholten, Christiane Cordes, Maria Martinez-Rebollar, Christoph D. Spinner, Mark Nelson, Michael Rausch, Sanjay Bhagani, Lars Peters, Thomas Reiberger, Stefan Mauss, Juergen K. Rockstroh, Christoph Boesecke

Summary: This study analyzed the spontaneous clearance rates and predictors of spontaneous clearance in recently acquired hepatitis C virus (HCV) infections among HIV-positive men who have sex with men (MSM). The findings showed that spontaneous clearance is infrequent in this population, highlighting the importance of early antiviral treatment.

CLINICAL INFECTIOUS DISEASES (2023)

Letter Gastroenterology & Hepatology

Letter: chronic HDV infection-is ignorance bliss? Authors' reply

Mathias Jachs, Thomas Reiberger, Peter Ferenci

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Review Gastroenterology & Hepatology

The Baveno VII concept of cirrhosis recompensation

Thomas Reiberger, Benedikt Silvester Hofer

Summary: Traditionally, compensated to decompensated cirrhosis was considered irreversible, but new evidence challenges this view, showing disease regression and hepatic recompensation upon suppression/cure of the underlying cause. The Baveno VII consensus established standardized criteria for recompensated cirrhosis, including removal of the primary cause, resolution of decompensating events, and sustained improvement in hepatic function. Initial studies suggest that suppressing/curing the cause can lead to significant clinical improvements, favorable outcomes, and even removal from the transplant candidate list. Future research is needed to understand the natural history of hepatic recompensation, identify modifying factors and potential biomarkers, and explore molecular mechanisms of disease regression.

DIGESTIVE AND LIVER DISEASE (2023)

Article Gastroenterology & Hepatology

Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis

Georg Semmler, Bernhard Scheiner, Lorenz Balcar, Rafael Paternostro, Benedikt Simbrunner, Matthias Pinter, Michael Trauner, Marta Bofill Roig, Elias Laurin Meyer, Benedikt Silvester Hofer, Mattias Mandorfer, David James Pinato, Christian Zauner, Thomas Reiberger, Georg-Christian Funk

Summary: This study confirms the association between hypochloremia and prognosis in patients with cirrhosis, both in clinically stable patients and critically ill cases.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Endoscopic band ligation is safe despite low platelet count and high INR

Nikolaus Pfisterer, Michael Schwarz, Mathias Jachs, Florian Putre, Lukas Ritt, Mattias Mandorfer, Christian Madl, Michael Trauner, Thomas Reiberger

Summary: Prophylactic endoscopic band ligation (EBL) is a safe procedure to prevent variceal bleeding in cirrhotic patients, even in the presence of thrombocytopenia or high INR. The risk of EBL-related bleeding is mainly associated with high MELD and bilirubin levels, but not with platelet count, INR, or non-selective beta-blocker use.

HEPATOLOGY INTERNATIONAL (2023)

Review Gastroenterology & Hepatology

Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension

Laura Turco, Thomas Reiberger, Giovanni Vitale, Vincenzo La Mura

Summary: Portal hypertension is a common complication of cirrhosis and plays a crucial role in hepatic decompensation. Carvedilol, a non-selective beta-blocker, has shown superior efficacy in reducing portal hypertension compared to traditional beta-blockers, making it a preferred treatment option for clinically significant portal hypertension in patients with cirrhosis.

LIVER INTERNATIONAL (2023)

Article Multidisciplinary Sciences

Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients

Lorenz Balcar, David Bauer, Katharina Pomej, Tobias Meischl, Mattias Mandorfer, Thomas Reiberger, Michael Trauner, Bernhard Scheiner, Matthias Pinter

Summary: Immunotherapy is the new standard of care for hepatocellular carcinoma, but there is a need for biomarkers that predict treatment response and survival. This study suggests that the relative change in IgG after ICI treatment can serve as a negative prognostic marker in patients with HCC.

PLOS ONE (2023)

Editorial Material Gastroenterology & Hepatology

Editorial: Negative impact of diabetes mellitus and obesity on the prognosis of patients with chronic liver disease-Authors' reply

Rafael Paternostro, Mathias Jachs, Thomas Reiberger, Mattias Mandorfer

Summary: This article is linked to the papers by Paternostro et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Letter Gastroenterology & Hepatology

Letter: NSBB for fatty liver disease-Still a long way to go. Authors' reply

Mathias Jachs, Rafael Paternostro, Thomas Reiberger, Mattias Mandorfer

Summary: This article is linked to the papers by Paternostro et al, providing links to view these papers.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Letter Gastroenterology & Hepatology

Reply to: 3P and 5P models of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta

Mathias Jachs, Mattias Mandorfer, Thomas Reiberger

JOURNAL OF HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis

Antonio Guerrero, Laura del Campo, Fabio Piscaglia, Bernhard Scheiner, Guohong Han, Francesco Violi, Carlos-Noronha Ferreira, Luis Tellez, Thomas Reiberger, Stefania Basili, Javier Zamora, Agustin Albillos

Summary: This study used an individual patient data meta-analysis to demonstrate the safety and efficacy of anticoagulation in the recanalization of portal vein thrombosis in patients with cirrhosis. Anticoagulation reduces all-cause mortality, but at the expense of increasing non-portal hypertension-related bleeding.

JOURNAL OF HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Limited access to liver transplantation and TIPS despite high mortality, healthcare resource use and costs of cirrhosis in Germany

Christian M. M. Lange, Jonel Trebicka, Alexander Gerbes, Ali Canbay, Andreas Geier, Uta Merle, Markus Peck-Radosavljevic, Frank Tacke, Tobias Vogelmann, Sina Theis, Hartmut Heinze, Alexander Zipprich

Summary: Limited data is available on patients with cirrhosis in Germany. This study aimed to estimate the prevalence, comorbidities, mortality, healthcare resource utilization, and costs of these patients, as well as the incidence of decompensation of cirrhosis in Germany. The study found that the prevalence of cirrhosis in 2015 was 250/100,000, with an estimated 201,747 patients in the German population. Among patients with compensated cirrhosis, 16.0% developed decompensation within 3 years. Patients with decompensated cirrhosis had a higher burden of comorbidities and higher costs compared to patients with compensated cirrhosis. The 1-year mortality rate after decompensation was significantly higher than in patients with compensated cirrhosis. Only a small percentage of patients with decompensated cirrhosis received liver transplantation or transjugular intrahepatic portosystemic shunts (TIPS). Overall, patients with cirrhosis in Germany face a high healthcare burden, particularly in the decompensated stage.

LIVER INTERNATIONAL (2023)

Article Multidisciplinary Sciences

Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes

Michael Schwarz, Caroline Schwarz, Lukas Burghart, Nikolaus Pfisterer, David Bauer, Wolfgang Huebl, Mattias Mandorfer, Michael Gschwantler, Thomas Reiberger

Summary: This study assessed the characteristics of patients with liver cirrhosis at the time of first presentation and during their clinical course. The study found that half of the patients had decompensated cirrhosis at presentation, highlighting the need for increased awareness and strategies for earlier diagnosis of chronic liver disease and cirrhosis.

PLOS ONE (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Imaging features facilitate diagnosis of porto-sinusoidal vascular disorder

Katharina Lampichler, Georg Semmler, Katharina Woeran, Benedikt Simbrunner, Mathias Jachs, Lukas Hartl, David Josef Maria Bauer, Lorenz Balcar, Lukas Burghart, Michael Trauner, Dietmar Tamandl, Ahmed Ba-Ssalamah, Mattias Mandorfer, Thomas Reiberger, Bernhard Scheiner, Martina Scharitzer

Summary: This study aimed to compare the radiological features between PSVD and cirrhosis. The results showed that compared to cirrhosis, patients with PSVD were younger and had lower HVPG, liver stiffness, and MELD. CT/MRI results revealed that PSVD patients had more intrahepatic portal tract abnormalities, FNH-like lesions, and abnormal liver morphology. A specific radiological feature of PSVD identified in gadoxetic acid-enhanced MRI was periportal hyperintensity in the HBP.

EUROPEAN RADIOLOGY (2023)

No Data Available